Suppr超能文献

用NFAT诱导的膜结合IL-15/IL-21工程改造的靶向GPC2的CAR T细胞对神经母细胞瘤表现出增强的活性。

GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL-15/IL-21 exhibit enhanced activity against neuroblastoma.

作者信息

Okada Reona, Reyes-González Jeyshka M, Rodriguez Constanza, Kondo Taisuke, Oh Jangsuk, Sun Ming, Kelly Michael C, Zhang Ling, Gulley James L, Shern Jack F, Ho Mitchell, Hinrichs Christian S, Taylor Naomi N, Zhang Xiyuan, Nguyen Rosa

机构信息

National Cancer Institute, Bethesda, United States.

National Cancer Institute, Bethesda, Maryland, United States.

出版信息

Cancer Immunol Res. 2025 Jun 26. doi: 10.1158/2326-6066.CIR-24-0975.

Abstract

Neuroblastoma (NB) is a highly aggressive childhood solid tumor with poor outcomes. Chimeric antigen receptor (CAR) T cells have shown limited efficacy in NB, with the best outcomes reported in patients with a low tumor burden, highlighting the need for further CAR optimization. One approach to addressing the high tumor burden involves engineering CAR T cells to release or express transgenic cytokines. However, its systemic toxicity remains an important therapeutic challenge. Here, we evaluated the efficacy of interleukin (IL)-15- and IL-21-enhanced glypican-2 (GPC2)-targeted CAR T cells (GPC2-CAR T cells) in targeting high-burden NB. Three strategies for expressing the cytokines were evaluated: constitutive secretion (GPC2-CAR+sol.IL15.IL21), constitutive membrane-tethered expression (GPC2-CAR+teth.IL15.IL21), and NFAT-inducible membrane-tethered expression (GPC2-CAR+NFAT.IL15.IL21). Engineered GPC2-CAR T cells were tested in vitro and in vivo using high NB-burden xenograft models. Additionally, single-cell RNA sequencing was used to profile the effector cells in the tumor microenvironment. All three versions of GPC2-CAR T cells significantly enhanced killing against a high NB burden, both in vitro and in vivo, relative to control GPC2-CAR T cells. Mice treated with GPC2-CAR+NFAT.IL15.IL21 exhibited significantly lower anorexia-associated morbidity/mortality. Supporting these data, tumor-infiltrating GPC2-CAR+NFAT.IL15.IL21 developed an immunosuppressive transcriptional profile upon tumor regression, leading to prolonged survival in treated mice. In contrast, GPC2-CAR+teth.IL15.IL21 maintained a pro-inflammatory transcriptional signature despite near tumor clearance, resulting in hypercytokinemia and death. NFAT-inducible co-expression of tethered IL-15/IL-21 enhanced GPC2-CAR T-cell function against a high NB burden with acceptable tolerability in mice. Further studies are required to validate these findings.

摘要

神经母细胞瘤(NB)是一种侵袭性很强的儿童实体瘤,预后较差。嵌合抗原受体(CAR)T细胞在NB中的疗效有限,在肿瘤负荷低的患者中报告的疗效最佳,这突出表明需要进一步优化CAR。一种应对高肿瘤负荷的方法是对CAR T细胞进行工程改造,使其释放或表达转基因细胞因子。然而,其全身毒性仍然是一个重要的治疗挑战。在这里,我们评估了白细胞介素(IL)-15和IL-21增强的磷脂酰肌醇蛋白聚糖-2(GPC2)靶向CAR T细胞(GPC2-CAR T细胞)在靶向高负荷NB方面的疗效。评估了三种表达细胞因子的策略:组成型分泌(GPC2-CAR+sol.IL15.IL21)、组成型膜锚定表达(GPC2-CAR+teth.IL15.IL21)和NFAT诱导的膜锚定表达(GPC2-CAR+NFAT.IL15.IL21)。使用高NB负荷异种移植模型在体外和体内对工程化的GPC2-CAR T细胞进行了测试。此外,单细胞RNA测序用于分析肿瘤微环境中的效应细胞。相对于对照GPC2-CAR T细胞,所有三个版本的GPC2-CAR T细胞在体外和体内均显著增强了对高NB负荷的杀伤作用。用GPC2-CAR+NFAT.IL15.IL21治疗的小鼠表现出与厌食相关的发病率/死亡率显著降低。支持这些数据的是,肿瘤浸润的GPC2-CAR+NFAT.IL15.IL21在肿瘤消退后形成了免疫抑制转录谱,导致治疗小鼠的生存期延长。相比之下,尽管肿瘤几乎清除,但GPC2-CAR+teth.IL15.IL21仍保持促炎转录特征,导致细胞因子血症和死亡。NFAT诱导的拴系IL-15/IL-21共表达增强了GPC2-CAR T细胞对高NB负荷的功能,且在小鼠中具有可接受的耐受性。需要进一步研究来验证这些发现。

相似文献

2
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.
Front Immunol. 2025 Jul 31;16:1579925. doi: 10.3389/fimmu.2025.1579925. eCollection 2025.
4
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Cancer Immunol Res. 2019 Mar;7(3):363-375. doi: 10.1158/2326-6066.CIR-18-0572. Epub 2019 Jan 16.
5
Inhibition of autophagy enhances the antitumor efficacy of T/CAR T cell against neuroblastoma.
J Exp Clin Cancer Res. 2025 Jul 3;44(1):185. doi: 10.1186/s13046-025-03453-0.
8
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Cancer Immunol Res. 2020 Mar;8(3):309-320. doi: 10.1158/2326-6066.CIR-19-0293. Epub 2020 Jan 17.
9
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.
Cancer Immunol Res. 2025 Aug 1;13(8):1132-1144. doi: 10.1158/2326-6066.CIR-24-0876.

本文引用的文献

1
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872.
3
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859.
4
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
J Clin Invest. 2023 May 1;133(9):e166028. doi: 10.1172/JCI166028.
5
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005881.
6
Synthetic cytokine circuits that drive T cells into immune-excluded tumors.
Science. 2022 Dec 16;378(6625):eaba1624. doi: 10.1126/science.aba1624.
7
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.
Cancer Cell. 2022 Dec 12;40(12):1470-1487.e7. doi: 10.1016/j.ccell.2022.11.006.
8
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30.
9
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models.
STAR Protoc. 2021 Nov 10;2(4):100942. doi: 10.1016/j.xpro.2021.100942. eCollection 2021 Dec 17.
10
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Cell Rep Med. 2021 Jun 1;2(6):100297. doi: 10.1016/j.xcrm.2021.100297. eCollection 2021 Jun 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验